Overview

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
Phase:
Phase 1
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
Treatments:
Certolizumab Pegol